- Home
- MCRI vs JANX Comparison
MCRI vs JANX Comparison
Compare MCRI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- JANX
- Stock Information
- Founded
- MCRI 1972
- JANX 2017
- Country
- MCRI United States
- JANX United States
- Employees
- MCRI N/A
- JANX N/A
- Industry
- MCRI Hotels/Resorts
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- JANX Health Care
- Exchange
- MCRI Nasdaq
- JANX Nasdaq
- Market Cap
- MCRI 1.6B
- JANX 1.4B
- IPO Year
- MCRI 1993
- JANX 2021
- Fundamental
- Price
- MCRI $86.57
- JANX $25.79
- Analyst Decision
- MCRI Hold
- JANX Strong Buy
- Analyst Count
- MCRI 5
- JANX 8
- Target Price
- MCRI $88.60
- JANX $90.63
- AVG Volume (30 Days)
- MCRI 110.0K
- JANX 728.0K
- Earning Date
- MCRI 07-16-2025
- JANX 08-06-2025
- Dividend Yield
- MCRI 1.39%
- JANX N/A
- EPS Growth
- MCRI N/A
- JANX N/A
- EPS
- MCRI 3.96
- JANX N/A
- Revenue
- MCRI $525,923,000.00
- JANX $9,336,000.00
- Revenue This Year
- MCRI $4.32
- JANX N/A
- Revenue Next Year
- MCRI $2.41
- JANX $1,470.82
- P/E Ratio
- MCRI $21.75
- JANX N/A
- Revenue Growth
- MCRI 3.84
- JANX 28.12
- 52 Week Low
- MCRI $67.14
- JANX $22.48
- 52 Week High
- MCRI $96.11
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- MCRI 51.87
- JANX 61.29
- Support Level
- MCRI $86.11
- JANX $24.80
- Resistance Level
- MCRI $90.36
- JANX $24.87
- Average True Range (ATR)
- MCRI 1.83
- JANX 1.09
- MACD
- MCRI -0.27
- JANX 0.40
- Stochastic Oscillator
- MCRI 27.89
- JANX 92.70
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.